Last reviewed · How we verify

NCT04206917

MultiPulse Therapy (MPT) for AF

Terminated NA Last updated 14 October 2022
What this trial tests

NA trial testing Multi Pulse Therapy in Atrial Fibrillation, Paroxysmal in 30 participants. Terminated before completion.

Timeline
19 March 2020
Primary endpoint
21 June 2022
21 June 2022

Quick facts

Lead sponsorCardialen, Inc.
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment30
Start date19 March 2020
Primary completion21 June 2022
Estimated completion21 June 2022
Sites6 locations across Australia

Drugs / interventions tested

Conditions studied

Sponsor

Cardialen, Inc.

Who can join

Adults 18 to 80, any sex, with Atrial Fibrillation, Paroxysmal or Atrial Fibrillation, Persistent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assess the clinical safety and feasibility of MultiPulse Therapy (MPT) electrical stimulation waveform sequence in terminating paroxysmal and persistent atrial fibrillation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Cardialen, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04206917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing